Skip to main content

Market Overview

Alere Announces Settlement with SEC


WALTHAM, Mass., Sept. 28, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached a settlement with the United States Securities and Exchange Commission (the "SEC") in connection with the SEC's previously disclosed investigation. The SEC investigation primarily involved certain accounting and other matters occurring at foreign subsidiaries previously acquired by the Company.

Alere issued the following statement:

We have cooperated with the SEC and we are pleased to fully resolve this matter.

Under the terms of the settlement, Alere agreed to pay approximately $13 million to the SEC and consented to the entry by the SEC of an administrative cease-and-desist order, issued today by the SEC, without admitting or denying the findings in the order.

About Alere 
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers reliable and actionable information by providing rapid diagnostic tests, enhancing clinical and economic healthcare outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for cardiometabolic disease, infectious disease and toxicology.                
For more information on Alere, please visit


View original content:

SOURCE Alere Inc.

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at